Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. - Wikidata - wikimedia - TriplyDB

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.

http://www.wikidata.org/entity/Q38107524

about

A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide-Should Consideration Be Given to Cannalicular Efflux Transporters?Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine.Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.Intracellular CD3+ T Lymphocyte Teriflunomide Concentration Is Poorly Correlated with and Has Greater Variability Than Unbound Plasma Teriflunomide Concentration.Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis.

P2860

Q30716854-977B179D-7516-44FE-90F1-1EEB71DDE255 Q35861714-95D0A9FE-07CB-4939-A4BE-44497291169E Q36223948-C5635742-46F2-4164-82CB-EC76F2253CC3 Q36410232-89EBF0E0-F4BE-4F41-8E79-9FA4003F5E83 Q37071461-CB5925F7-D212-4C3D-A116-7611986F63CD Q38218692-3FC6AF20-6DE2-4621-81F0-9603ADE61E92 Q38357590-AF58615E-C3AC-4BED-8544-989A5A7F8B0C Q39032639-9CE4311C-6EC2-43E9-A376-83F2F3BD553B Q51771540-7B48EE73-37B4-4E82-8C81-EDB917FDA9DC Q53662070-27245916-1B84-4400-9FC9-40A18A4F6AC5

P2860

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.

http://www.wikidata.org/entity/Q38107524

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.

@en

type

label

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.

@en

prefLabel

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.

@en

P1433

Q38107524-8F4B47BE-BCE5-4D8C-B63C-2F0006A1228A

P1476

Q38107524-02CEE442-0ADD-429D-B1DB-8AA95047D8E8

P2093

Q38107524-3B4AF860-6B74-4515-9E6F-0224FAA99311

Q38107524-CA37F590-C28D-48B4-9A8C-4107605DB5DE

P2860

Q38107524-01627F31-75C8-4937-943B-4B2EFE5877D8

Q38107524-0ADC9806-677A-4B19-81BB-36D5227847E6

Q38107524-0CE0855F-1793-4747-A2E0-C2BF95FDC967

Q38107524-0E5D08E7-2CB7-4550-AE57-F643530EFE6A

Q38107524-0E72F979-C053-478E-9C76-D2347DFA6D1A

Q38107524-136DDA1D-5AB0-41E7-9FD3-8ECC86FB312B

Q38107524-1B07CCEB-ABD7-46B8-8826-6D28358AD7EA

Q38107524-1D340461-F0C5-45DE-A72E-97000369EBB4

Q38107524-220C6993-DC90-4219-BA73-1E1A629A894A

Q38107524-23C1370F-3B30-40D0-803E-6C2A4FD5E320

P304

Q38107524-59BB7E3F-F52B-4861-B7C9-48062CCA6EFE

P31

Q38107524-E9632392-8C68-4375-A758-53DF06216F3C

P356

Q38107524-208F0715-8F6B-4853-92B8-EB2DDBFBDCDF

P407

Q38107524-21621C41-FE4C-4BE9-8557-E607207DC986

P433

Q38107524-BD62FF58-6434-41C8-AE95-4C221834134F

P478

Q38107524-D5827C6E-5B01-4A8B-962E-823BBC80ED5F

P50

Q38107524-0071D1BF-F10E-4360-A8D4-67D28C9AFD90

Q38107524-08BB5996-58B7-433F-BBFA-B76BE71F3C6B

Q38107524-7BEE1321-AD00-45DF-95E1-4A6126DD397A

P577

Q38107524-68558A80-5D4E-40B6-92E2-F9E5FDE951B3

P5875

Q38107524-F006F44C-9E36-4A79-87F6-92E4F5B51C41

P698

Q38107524-335B9199-87DB-40E6-B785-76EE652FD6C9

P921

Q38107524-9C8A6425-8207-4F7E-B2FC-6DDF7673C96C

P356

17425255.2013.800483

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis

@en

P2093

Catherine O'Doherty

http://www.w3.org/2001/XMLSchema#string

Thomas M Polasek

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

Exome sequencing identifies the cause of a mendelian disorder

Mechanism of action for leflunomide in rheumatoid arthritis

Clinical pharmacokinetics of leflunomide

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

P304

1025-1035

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2013.800483

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Michael J. Sorich

Michael D Wiese

P577

2013-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236917304

http://www.w3.org/2001/XMLSchema#string

P698

23682862

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis